Specific activities have been developed and/or implemented by Inserm in order to meet the needs of the French national plans.
The 2014-2019 Cancer Plan primarily aspires to meet the needs and expectations of patients, their friends and family, and society as a whole. It aims to cure, but also to support the individual and their friends and family, through research and prevention. Inserm is involved not only in carrying out and funding research activities at the French National Cancer Institute, but also as a crucial player through its own research teams.
The French Plan for Genomic Medicine 2025, developed by Inserm and its Aviesan partners, aims to expand the use of whole genome sequencing in clinical practice. From now until 2025, 60,000 genomes will be decoded every year, in order to strengthen personalized medicine.
The Interministerial Antibiotic Resistance Management Program aims to slash the use of antibiotics by 25% by 2018, and to reduce the health and environmental consequences of antibiotic resistance. Inserm is involved in the operational steering of measures relating to research and innovation in managing antibiotic resistance, and in its assessment and monitoring.
Implementation of a Public Health Research Plan
Among the objectives set out in its 2020 Strategic Plan, Inserm aims to strengthen its strategic steering tools in the area of public health: a field that aims to understand how health, well-being, and the efficiency of the health-care system can be improved. This program is based on four coherent approaches that will receive high-priority support in order to strengthen the international visibility and reactivity of French public health research:
- determinants of health, prevention, and interventional research
- health, work, and environmental interactions
- innovation and organization of health services and public policies
- concepts and methods in emerging and innovative fields